TY - JOUR T1 - Meta-analysis evaluating the risk of respiratory tract infections and acute respiratory distress syndrome with glucagon-like peptide-1 receptor agonists in cardiovascular outcome trials: Useful implications for the COVID-19 pandemic JO - Revista Clínica Española (English Edition) T2 - AU - Patoulias,D. AU - Boulmpou,A. AU - Imprialos,K. AU - Stavropoulos,K. AU - Papadopoulos,C. AU - Doumas,M. SN - 22548874 M3 - 10.1016/j.rceng.2021.04.002 DO - 10.1016/j.rceng.2021.04.002 UR - https://revclinesp.es/en-meta-analysis-evaluating-risk-respiratory-tract-articulo-S2254887421001016 AB - Patients with type 2 diabetes mellitus (T2DM) are at increased risk for severe coronavirus disease 2019 (COVID-19) and related mortality. Glucagon-like peptide-1 receptor agonists (GLP-1-RAs) have significant cardiovascular and renal benefits for patients with T2DM and related comorbidities. Their anti-inflammatory properties could be beneficial in these patients. This work provides less-biased estimates regarding the risk for respiratory tract infections and acute respiratory distress syndrome by performing the first significant meta-analysis of cardiovascular outcome trials in the literature. Notably, GLP-1-RAs do not seem to increase the risk for respiratory tract infection, pneumonia, or acute respiratory distress syndrome in patients with T2DM and cardiovascular comorbidities. ER -